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patients. 120 Moreover, cognitive impairment is often associated with LGGs, 51, 121 with patients experiencing deterioration in a broad array of cognitive domains (e.g. information processing, attention, psychomotor speed, and memory) when compared with control groups. 51, 121, 122 While the prognostic value of cognitive functioning has been demonstrated for survival in glioma patients, [53] [54] [55] [56] relatively little is known about its relation to patients' everyday life functioning.
A small study among long-term survivors of malignant supratentorial brain tumors suggests that even subtle cognitive deficits might hamper a patient's autonomy and professional life. 58 In addition, indices of neurological functioning, such as epilepsy burden, have been shown to be related to both lower objective cognitive functioning and self-reported health-related quality of life (HRQOL) in LGG patients. 123 With the high incidence of cognitive and neurological deficits and poorer self-reported HRQOL in LGG patients, 31, 124 a relationship between cognitive functioning and generic and disease-specific HRQOL would be expected. However, to our knowledge, these associations have not yet been examined in depth. Previous studies that examined both cognitive functioning and HRQOL did not formulate these associations to be their primary study objective and consequently yielded only brief reports with little detail. 31, 123 However, it is of particular importance to know the clinical and functional significance of cognitive impairment for clinicians and patients. The clinical relevance of cognitive deficits cannot be fully appreciated without assessing their impact on the patient's quality of life. Apart from these possible clinical implications, a separate investigation into the nature and strength of the correlation between these factors is also merited because of the increased value being attributed to both cognitive functioning and HRQOL as secondary endpoints in glioma clinical trials.
24, 25
maTerials and meThods participants Data for this study were collected as part of a nationwide study of cognitive functioning and HRQOL of glioma patients. The methodology of these studies has been described in detail elsewhere. 121 In short, LGG patients were diagnosed on average six years prior to data collection and were included in the study if they had: (1) been diagnosed with a histologically confirmed low-grade astrocytoma, oligodendroglioma, or oligoastrocytoma at least one year prior to study entry; (2) no clinical signs of tumor recurrence for at least 1 year after diagnosis and primary treatment; (3) no radiological
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signs of recurrence within 3 months before the first assessments were performed, (4) no current treatment with corticosteroids; and (5) basic proficiency in the Dutch language.
In addition, we included data from two samples of healthy controls. Specifically, for comparison on cognitive performance, we employed a reference sample from the Maastricht Aging Study, 125 a large cross-sectional study on the biological and psychological determinants of cognitive aging. Reference data for the HRQOL assessments were selected from a national study aimed at constructing a Dutch version of the Short-Form Health Survey. 19 All healthy controls were matched to the patient group for age, sex, and educational level.
procedure
Patients were asked to provide information about their sociodemographic background via a structured interview. Clinical data were obtained from the medical records. Patients completed the self-report measures of generic (SF36) and disease specific (BN20) HRQOL and the neuropsychological tests either at home or at their treating hospital. Neuropsychological assessments were performed by a trained test assistant who was supervised by a board certified neuropsychologist (M.K.). The institutional review boards of the participating centers approved the research protocol and all participants provided written, informed consent.
outcome measures
Cognitive performance was assessed using an extensive battery of standardized neuropsychological tests, described in detail in Table 1 22 This module contains four multi-item scales (future uncertainty, visual disorders, motor dysfunctions, communication deficits) and seven single items assessing headaches, seizures, drowsiness, hair loss, itching, weakness in the legs, and difficulties with bladder control. Scores range from 0 to 100, with higher scores indicating more symptoms. The BN20 scales have high internal consistency reliability (alpha > 0.70) and show overall adequate psychometric properties. 22 Although the BN20 is often administered alongside the EORTC QLQ-C30, unfortunately, we have no data regarding this cancer-specific HRQOL questionnaire.
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Cognitive funCtioning and HRQoL in Lgg patients statistical analysis
All statistical analyses were performed using the Statistical Package for Social Science version 20.0 (SPSS). Standard scoring rules were used to convert the data from the questionnaires. The neuropsychological test scores were transformed into Z-scores using the mean and standard deviations (SDs) of the healthy controls, and six cognitive domains were created for the purpose of data reduction (Table 1) . To calculate each domain, Z-scores of the outcome variables were summed up and divided by the number of variables per domain. Higher scores indicate better performance in all domains. Sociodemographic characteristics, HRQOL and cognitive functioning of the LGG group and the control groups were compared using univariate analysis of variance (ANOVA) and the Chi square statistic. A two-sided p-value less than 0.05 was considered significant. To examine the associations between cognitive functioning and both generic (SF36 component summaries MCS and PCS) and disease-specific HRQOL (BN20 scales future uncertainty, visual disorders, motor dysfunctions, communication deficits, headaches, seizures, and drowsiness), Pearson correlations were calculated. To adjust for multiple testing, corrections were applied for the six 
resulTs demographic characteristics
In total, 239 eligible LGG patients were invited for participation, of which 82% (N=195) were included in the study. The main reasons reported for declining participation were the perceived burden of participating and not wanting to be confronted with their disease history. In 5 cases, data were incomplete, leaving 190 LGG patients for the present analyses. No statistically significant differences between the patients and the healthy controls were found for age, gender, and educational level, indicating an adequate matching procedure (see Table 2 ). Most
LGG patients were men (61.5%), and most received middle to high levels of education. The majority of patients were married or lived together with their partner (63.6%).
cognitive functioning and hrqol
LGG participants had lower scores than healthy controls on all cognitive domains that were assessed (p<0.001 for all domains except the verbal memory domain (p=0.009)), see Figure  1 . Furthermore, we found lower self-reported mental health in LGG patients (MCS; M=46.09, sd=9.81) than in healthy controls (M=49. 91, sd=9.92, p<0.001) . No statistically significant differences were observed in physical health between LGG patients and healthy controls (PCS; M=49.92, sd=9.11 vs M=51.28, sd=7.86, p=0.119) . 
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associations between cognitive functioning and generic (sf36) and disease-specific (Bn20) hrqol
Cognitive functioning and generic (SF36) HRQOL
Better performance on all of the cognitive domains we assessed was associated with significantly better self-reported physical health (Table 3 PCS; all p<0.001). Furthermore, better performance on executive functioning, processing speed, working memory capacity and information processing speed was associated with better mental health (MCS; r=0.270, r=0.318, r=0.250, and r=0.267 , respectively, all p≤0.001).
Cognitive functioning and disease-specific (BN20) HRQOL
Regarding cognitive functioning and disease-specific HRQOL as assessed by the BN20, many negative correlations of weak to moderate strength were found (see Table 4 ). All cognitive domains were negatively correlated with the BN20 scales for uncertainty concerning the future, motor dysfunctions, and seizures. This indicates that worse cognitive performance is associated with more symptoms, as assessed by these scales.
Patients who had lower executive functioning, processing speed, working memory capacity, information processing speed, and attentional functioning were characterized by more symptoms of visual disorders. Furthermore, worse performance on information processing tasks and attention tasks was related to more difficulty with communication. Patients who had a lower information processing speed also reported more drowsiness.
discussion
It is often assumed, but has never actually been demonstrated, that cognitive functioning in brain tumor patients is related to their HRQOL. We tested this assumption in a large cohort of low-grade glioma patients with stable disease, at an average of six years after diagnosis. We found that many aspects of physical functioning, as measured with the SF36 and BN20, were associated with many, if not all, cognitive domains. Furthermore, poorer mental health (MCS) and more uncertainty concerning the future were related to lower cognitive functioning. These results suggest that LGG patients in a stable phase of their disease may be bothered by cognitive deficits that negatively affect their everyday life functioning. The present study outcomes concur with those of Giovagnoli and Boiardi, 58 who reported that asymptomatic, long-term glioma survivors may experience limitations in their autonomy, even with subtle cognitive deficits. In addition, severe cognitive dysfunction was related to worse levels of HRQOL in patients with a benign (WHO grade I) meningioma.
132
This report, as well as our previous report on this LGG patient cohort, 121 demonstrates that cognitive deficits are present in LGG patients in a period of stable disease and that their performance on cognitive tests is statistically significantly worse than of healthy controls. However, the deficits found are, on a group level, relatively mild. In fact, the Z-scores on all domains tested do not exceed 1.5 SD below the mean of healthy controls (the threshold often used in the patient context to define clinically significant cognitive dysfunction). Memory deficits in particular seem less prominently present in our cohort than in other publications on glioma patients. 8, 133 One explanation for this particular difference could be the use of a different neuropsychological test. We tested verbal memory using visually presented stimuli, while other reports frequently use verbal auditory-presented stimuli. While still measuring the same construct (i.e., verbal memory), a bias in results based on this difference cannot be excluded. In addition, the reduction found in mental health does not exceed a standard deviation below the mean and hence probably reflects only subtle compromise. Nevertheless, while cognitive deficits and compromise in HRQOL may be subtle in nature, the present report demonstrates the highly correlated relationship of cognitive functioning and both generic and disease-specific HRQOL. With most correlations being of moderate strength, it seems likely that LGG patients with stable disease, who resumed their daily activities, may be more aware of 
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subtle or more pronounced negative changes in their cognitive abilities. We suspect that the priorities of LGG patients may shift along with their view of the immediate and more distant future. However, these hypotheses cannot be confirmed by the present study due to its crosssectional nature. Thus, additional longitudinal studies are needed. Alternatively, in part, the associations found may be explained by the nature of the neuropsychological tests and the neurological disabilities of the patients. Visual and motor deficits in particular may contribute to poorer performance on certain cognitive tasks that for a great deal depend on these skills, such as tests assessing attentional functioning. Indeed, poor performance on timed tasks in these patients can be attributed, in large part, to visual and motor deficits. 9 Where possible, interventions to improve functioning in these areas may potentially contribute to better cognitive functioning as well as better HRQOL. We only investigated the association between HRQOL and cognitive functioning in this study; it is likely that this association is confounded by other patient-related factors like fatigue, sleep quality, anxiety, depression, and instrumental activities of daily living (IADL), which have been reported to affect the daily lives of patients as well. 12, 13, 122, 134 Although it is not yet available as a validated instrument, a brain-tumor specific measure of IADL is currently being developed at our institution. Because this test includes adapted items based on IADL assessment in patients with dementia and focuses on their everyday functional impairment resulting from cognitive deficits, it could prove to be a highly relevant tool in the future in clinical practice and the research setting.
In conclusion, our results indicate that when cognitive functioning is worse, LGG patients who are in a stable phase of their disease experience worse physical and mental HRQOL. Furthermore, LGG patients who experience more cognitive deficits also report more issues with disease-specific HRQOL, which is most pronounced in the scales future uncertainty, motor dysfunction, visual disorders, and seizures. Future longitudinal studies should include measures of anxiety and depression, fatigue, IADL, demographic characteristics and clinical variables in order to assess which other factors have an effect on these associations. While beyond the scope of the present study, examining associations between cognitive functioning and subscales, rather than summary scales of generic HRQOL could provide additional information in future studies. Maintaining or even improving HRQOL by preventing long-term cognitive sequelae, or rehabilitation of cognitive deficits if prevention is not feasible, is an important goal in the treatment of glioma patients. It is important to understand the functional significance of cognitive impairments in the everyday lives of LGG patients. Cognitive assessment of patients with gliomas cannot -or rather, should not -be performed in isolation from assessment of its impact on psychosocial functioning and HRQOL. 
